Zevra Therapeutics, Inc. ZVRA 深 滬
已收盤 08-07 16:00:00 美东时间
11.56
-0.320
-2.69%
華盛通- 最 高11.9704
- 今 開11.91
- 成交量 126.29万股
- 最 低 11.35
- 昨 收 11.88
- 總市值 6.83亿
- 52周最高 15.035
- 市盈率 靜 8.53
- 換手率 2.14%
- 52周最低 7.16
- 委 比 -2.94%
- 總股本 5911.51万
- 歷史最高 418.40
- 量 比 0.87
- 振 幅 5.22%
- 歷史最低 0.206
- 每 手 1
- 風險率 1.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Zevra Therapeutics Q2 EPS $0.14 Beats $0.11 Estimate, Sales $39.663M Beat $33.881M Estimate
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.11 by 27.27 percent. This is a 88.71 percent decrease over earnings of $1.24 per share from the same period last year. The company reported quarterly sales of $39.663 milli...
08-06 04:23
Zevra Therapeutics Announces Publication Of "Long-Term Real-World Safety And Effectiveness Of Arimoclomol In Individuals With NPC: Outcomes From US Early Access Program Over A 4-Year Period" In Molecular Genetics And Metabolism
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the publication of "Long-term real-world safety and effectiveness of arimoclomol in individuals with NPC: Out...
08-03 19:34
美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) shares are trading lower on Friday as the company faces challenges following a negative opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) regarding its Marketing Authorization Application for arimoclomol for Niem...
07-25 00:47
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
Zevra Therapeutics Announces Publication Of Arimoclomol In Infants With Niemann-Pick Disease Type C: Results From The Phase 2/3 Open-Label Pediatric Substudy In Molecular Genetics And Metabolism Reports
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, announced the publication of "Arimoclomol in infants with Niemann-Pick disease type C: Results from the phase 2/3 open-label ...
06-23 19:36
美股大行评级 | 高盛上调美光科技目标价从400美元升至900美元；斯马克、Cloudflare获多家公司上调目标价
今日重点评级关注：Ascendiant Capital：维持NextTrip"买入"评级，目标价从7美元升至7.5美元；Maxim Group：维持Zevra Therapeutics"买入"评级，目标价从25美元升至35美元
06-11 09:55
美股大行评级 | 潜在涨幅321.55%！Shattuck Labs获花旗升目标价至18美元，维持"买入"评级
今日重点评级关注：花旗：维持Shattuck Labs"买入"评级，目标价从7美元升至18美元；Benchmark：维持Gloo Holdings"买入"评级，目标价从14美元升至15美元
06-10 12:32
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
